Skip to content

Study · In vitro (cells) · pseudomonas aeruginosa · 2024

3 results

Mutations in genes lpxL1, bamA, and pmrB impair the susceptibility of cystic fibrosis strains of Pseudomonas aeruginosa to murepavadin.

Ghassani A, Triponney P, Bour M, Plésiat P, Jeannot K

Antimicrobial agents and chemotherapy11 Dec 2023Cited by 7 (Europe PMC)

PMID38092672 (opens in a new tab)PMCIDPMC10790571 (opens in a new tab)DOI10.1128/aac.01298-23 (opens in a new tab)PepBankPUB-38092672
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cystic fibrosis isolates, 9.1% of strains had murepavadin MIC >4 mg/L, versus a collection modal MIC ≤0.06 mg/L.

    In plain wordsIn lab tests, 9.1% of strains had murepavadin MIC >4 mg/L, compared with the collection modal value ≤0.06 mg/L.

    Peptide
    Murepavadin
    Outcome
    Not applicableMurepavadin susceptibility distribution
    Study

    Pseudomonas aeruginosan = 230

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Strains with MIC >4 mg/L
    9.1%
    CF isolates
    Modal MIC
    ≤ 0.06 mg/L
    whole collection

    Source sentences

    Summary
    Although murepavadin is still in preclinical stage of development, 9.1% (n = 21) of strains had a minimum inhibitory concentration (MIC) >4 mg/L, a level at least 128-fold higher than the modal MIC value of the whole collection (≤0.06 mg/L).
    1 context sentence
    Summary · context
    In the present study, its in vitro activity was assessed on 230 cystic fibrosis (CF) strains of Pseudomonas aeruginosa isolated from 12 French hospitals, in comparison with 12 other antipseudomonal antibiotics.

Studies that did not test the peptide alone2

In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Murepavadin.

  1. 02LabNot a test of Murepavadin aloneIn vitro (cells)Mechanism

    In PAO1 bacteria, lpxL1, bamA and/or pmrB alterations decreased murepavadin susceptibility by 8- to 32-fold.

    In plain wordsIn lab tests, gene alterations reduced bacterial susceptibility to murepavadin by 8- to 32-fold.

    Peptide
    Murepavadin
    Outcome
    DecreaseGene alterations and susceptibility
    Study

    Pseudomonas aeruginosan: not reported in source

    PAO1 allelic replacement experiments
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Allelic replacement experiments with wild-type reference strain PAO1 confirmed that alteration of genes lpxL1, bamA, and/or pmrB can decrease the murepavadin susceptibility from 8- to 32-fold.
    1 context sentence
    Summary · context
    In the present study, its in vitro activity was assessed on 230 cystic fibrosis (CF) strains of Pseudomonas aeruginosa isolated from 12 French hospitals, in comparison with 12 other antipseudomonal antibiotics.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

  2. 03LabNot a test of Murepavadin aloneIn vitro (cells)Mechanism

    In Pseudomonas aeruginosa, specific PmrB amino acid substitutions reduced susceptibility to murepavadin.

    In plain wordsIn lab tests, specific PmrB substitutions reduced bacterial susceptibility to murepavadin.

    Peptide
    Murepavadin
    Outcome
    DecreasePmrB substitutions and susceptibility
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Furthermore, we found that specific amino acid substitutions in histidine kinase PmrB (G188D, Q105P, and D45E) reduce the susceptibility of P. aeruginosa to murepavadin, colistin, and tobramycin, three antibiotics used or intended to be used (murepavadin) in aerosols to treat colonized CF patients.
    1 context sentence
    Summary · context
    In the present study, its in vitro activity was assessed on 230 cystic fibrosis (CF) strains of Pseudomonas aeruginosa isolated from 12 French hospitals, in comparison with 12 other antipseudomonal antibiotics.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.